News from mallinckrodt plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 17, 2022, 14:15 ET New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review ...

Apr 13, 2022, 06:45 ET Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled Nitric Oxide in Hospitalized COVID-19 Patients

Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced the publication of findings from a retrospective chart review...

Mar 28, 2022, 06:45 ET Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced the publication of findings from a retrospective medical...

Feb 22, 2022, 06:45 ET Mallinckrodt Provides a Regulatory Update on Terlipressin

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a...

Jan 31, 2022, 06:45 ET Mallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality Index

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, announced that it received a score of 100 on the Human Rights Campaign...

Dec 16, 2021, 06:45 ET Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness Burns

Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a...

Dec 13, 2021, 06:45 ET New Data on Patients with Cutaneous T-cell Lymphoma Treated with Extracorporeal Photopheresis from a Retrospective Study Presented at the American Society of Hematology Annual Meeting

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review ...

Nov 12, 2021, 08:00 ET Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital Experience

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies...

Oct 25, 2021, 06:45 ET Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study...

Sep 03, 2021, 06:16 ET Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders

Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of...

Jul 07, 2021, 06:45 ET Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016...

Jul 01, 2021, 07:46 ET Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary Sarcoidosis

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European...

May 03, 2021, 06:45 ET Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to...

Apr 30, 2021, 12:34 ET Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing...

Mar 29, 2021, 06:45 ET National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as...

Mar 24, 2021, 06:45 ET Mallinckrodt Supports Healthcare Businesswomen's Association as Two Employees Honored with Prominent Awards

Mallinckrodt plc, a global biopharmaceutical company, today announced that employees Tanya Hill, Executive Director, Commercial Strategy and Brand...

Mar 21, 2021, 23:56 ET Mallinckrodt gibt den Preisträger des 2021 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award bekannt

Mar 21, 2021, 23:46 ET Mallinckrodt annonce le prix 2021 du chercheur en immunomodulation pour l'avancement de la photophorèse extracorporelle

Mar 20, 2021, 15:31 ET Mallinckrodt anuncia su premio en investigación de inmunomodulación de fotoforesis extracorporal avanzada 2021

Mar 10, 2021, 06:45 ET Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans

Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien...

Mar 04, 2021, 06:45 ET Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the...

Feb 12, 2021, 06:45 ET Mallinckrodt Provides Regulatory Update on StrataGraft®

Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that...